Volume 24, Issue 3 (Jun 2016)                   JSSU 2016, 24(3): 277-285 | Back to browse issues page

XML Persian Abstract Print

Clinicopathological significance of plasminogen activator inhibitor-1 gene polymorphism in breast cancer patients from North West of Iran
M Younesi , MA Hosseinpour Feizi * , N Pouladi
Abstract:   (7752 Views)

Introduction: A common polymorphism 4G/5G in the promoter region of the Plasminogen activator inhibitor-1 (PAI-1) gene has been reported to influence the expression levels of PAI-1. According to the evidence, progression of breast cancer can be associated with elevated levels of PAI-1, it seems that evaluation of a possible correlation between the polymorphism and clinical status of breast cancer patients is reasonable.

Methods: This descriptive-analytical study included 160 unrelated patients from North West of Iran. According to established clinical criteria, these paitients were diagnosed with breast cancer. Based on previous study, PAI-1 4G/5G had been determined. In order to investigate the association of this polymorphism with clinicopathological features Fisher’s exact tests and SPSS software was used with a significance level of 0.05.

Results: All declared features of breast cancer regarding PAI-1 4G/5G polymorphism were investigated. Results indicated that PAI-1 4G/5G polymorphism positive correlation with several traditional prognostic factors, including tumor size, lymph node metastases and tumor stage.

Conclusion: Data showed that the patients with 5G/5G genotype are more susceptible to the development of breast cancer, while the paitients with 4G/4G and 4G/5G genotypes show lower sensitivity to the breast cancer. Therefore, the 4G allele likely has a protective role against the development of breast cancer in this cohort.

Keywords: PAI-1 4G/5G polymorphism, Breast Cancer, Clinical Status
Full-Text [PDF 611 kb]   (1822 Downloads)    
Type of Study: Original article | Subject: Genetics
Received: 2015/10/19 | Accepted: 2016/05/31 | Published: 2016/08/20
References
1. Blasiak J, Smolarz B. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Pol 2000; 47(1): 191-99.
2. Eroglu A, Ulu A, Cam R, Akar N. Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in patients with breast cancer. J BUON 2005; 11(4): 481-84.
3. Lei H, Hemminki K, Johansson R, Altieri A, Enquist K, Henriksson R, et al. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat 2008; 109(1): 165-75.
4. Shaghaghi Z, Bonyadi M, Somi MH, Khoshbaten M. Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azari Turkish patients. Saudi J Gastroenterol 2014; 20(1): 54-8.
5. Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006; 15(11): 2107-14.
6. Yasar Yildiz S, Kuru P, Toksoy Oner E, Agirbasli M. Functional stability of plasminogen activator inhibitor-1. SciWorld J 2014; 2014: 858293.
7. Lee JH, Kim Y, Choi JW, Kim YS. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Arch Med Res 2013; 44(1): 39-45.
8. Parpugga TK, Tatarunas V, Skipskis V, Kupstyte N, Zaliaduonyte-Peksiene D, Lesauskaite V. The effect of PAI-1 4G/5G polymorphism and clinical factors on coronary artery occlusion in myocardial infarction. Dis Markers 2015; 2015: 260101.
9. Castello R, Espana F, Vazquez C, Fuster C, Almenar SM, Aznar J, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006; 117(5): 487-92.
10. Xu X, Xie Y, Lin Y, Xu X, Zhu Y, Mao Y, et al. PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: evidence from meta-analysis. Exp Ther Med 2012; 4(6): 1127-33.
11. Wang S, Cao Q, Wang X, Li B, Tang M, Yuan W, et al. PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis. PLoS One 2013; 8(2): e56797.
12. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. pp. 347-76.
13. Younesi M, Hosseinpour Feizi MA, Pouladi N. Study of PAI-1 -675 4G/5G polymorphism in breast cancer patients from North West of Iran. Med J Tabriz Uni Med Sciences Health Services 2016; in press. (Persian)
14. Shaghaghi Z, Bonyadi M, Somi MH, Khoshbaten M. Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients. Saudi J Gastroenterol 2014; 20(1): 54-8.
15. Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009; 124(4): 403-08.
16. Zhang X, Shu XO, Cai Q, Ruan Z, Gao YT, Zheng W. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res 2006; 12(20): 6037-42.
17. Zhang H, Dong P, Yang X, Liu Z. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J Clin Exp Med 2014; 7(10): 3777-88.
18. Ozen F, Erdis E, Sik E, Silan F, Uludag A, Ozdemir O. Germ-line MTHFR C677T, FV H1299R and PAI-1 5G/4G variations in breast carcinoma. Asian Pac J Cancer Prev 2013; 14(5): 2903-08.
19. Yagmurdur MC, Atac FB, Tutar NU, Verdi H, Isiklar I, Ozdemir BH, et al. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast. Int Surg 2008; 93(3): 163-68.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.